| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698651 | Clinical Oncology | 2014 | 10 Pages |
Abstract
Bortezomib alone or in combination with other agents can be recommended for both previously untreated or relapsed/refractory patients with multiple myeloma. Guidelines for monitoring and reducing toxicity are provided.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
C.T. Kouroukis, F.G. Baldassarre, A.E. Haynes, K. Imrie, D.E. Reece, M.C. Cheung,